{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:52:43Z","timestamp":1788306763313,"version":"build-2803163510"},"reference-count":19,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>Trotz der glutenfreien Di\u00e4t leiden 30\u201350% der diagnostizierten Betroffenen weiterhin an Beschwerden \u2013 mit Zeichen der Entz\u00fcndung, u.a. wegen unvermeidbarer minimaler Gluten-Kontaminationen im Alltag.<\/jats:p><jats:p>Vielversprechende therapeutische Ans\u00e4tze sind zurzeit in klinischer Phase-2-Entwicklung, u.a. ein Hemmstoff der intestinalen TG2, blockierende Antik\u00f6rper gegen Interleukin-15 oder Ox40-Ligand, die Verbesserung der intestinalen Barriere mittels eines Sirtuin-6-Agonisten, sowie nanopartikul\u00e4re Therapien, die \u00fcber Adressierung der Milz oder Leber eine Toleranz gegen\u00fcber Gluten induzieren k\u00f6nnen.<\/jats:p>","DOI":"10.1055\/a-2318-8624","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:12:46Z","timestamp":1740183166000},"page":"273-279","source":"Crossref","is-referenced-by-count":1,"title":["Z\u00f6liakie: Neue pharmakologische Therapien"],"prefix":"10.1055","volume":"150","author":[{"given":"Detlef","family":"Schuppan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Neufang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Wanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1053\/j.gastro.2009.09.008","article-title":"Celiac disease: from pathogenesis to novel therapies","volume":"137","author":"D Schuppan","year":"2009","journal-title":"Gastroenterology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0140-6736(18)31894-4","article-title":"Coeliac disease","volume":"391","author":"B Lebwohl","year":"2018","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1053\/j.gastro.2021.08.016","article-title":"Co-factors, Microbes, and Immunogenetics in Celiac Disease to Guide Novel Approaches for Diagnosis and Treatment","volume":"161","author":"EF Verdu","year":"2021","journal-title":"Gastroenterology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/SGA.0000000000000377","article-title":"Persistent Symptoms in People With Celiac Disease Despite Gluten-Free Diet: A Concern?","volume":"42","author":"S Roos","year":"2019","journal-title":"Gastroenterol Nurs"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1053\/j.gastro.2024.02.050","article-title":"How Future Pharmacologic Therapies for Celiac Disease Will Complement the Gluten-Free Diet","volume":"167","author":"V Discepolo","year":"2024","journal-title":"Gastroenterology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/ajcn\/85.1.160","article-title":"A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease","volume":"85","author":"C Catassi","year":"2007","journal-title":"Am J Clin Nutr"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1053\/j.gastro.2019.03.046","article-title":"Many Patients With Irritable Bowel Syndrome Have Atypical Food Allergies Not Associated With Immunoglobulin E","volume":"157","author":"A Fritscher-Ravens","year":"2019","journal-title":"Gastroenterology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.gtc.2018.09.010","article-title":"Refractory Celiac Disease","volume":"48","author":"G Malamut","year":"2019","journal-title":"Gastroenterol Clin North Am"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/ajg.2014.29","article-title":"Patient perception of treatment burden is high in celiac disease compared with other common conditions","volume":"109","author":"S Shah","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/pbi.12837","article-title":"Low-gluten, nontransgenic wheat engineered with CRISPR\/Cas9","volume":"16","author":"S S\u00e1nchez-Le\u00f3n","year":"2018","journal-title":"Plant Biotechnol J"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1053\/j.gastro.2022.07.071","article-title":"Latiglutenase Protects the Mucosa and Attenuates Symptom Severity in Patients With Celiac Disease Exposed to a Gluten Challenge","volume":"163","author":"JA Murrray","year":"2022","journal-title":"Gastroenterology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1053\/j.gastro.2021.03.019","article-title":"Gluten Degradation, Pharmacokinetics, Safety, and Tolerability of TAK-062, an Engineered Enzyme to Treat Celiac Disease","volume":"161","author":"IS Pultz","year":"2021","journal-title":"Gastroenterology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S2468-1253(19)30264-X","article-title":"Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study","volume":"4","author":"M-L L\u00e4hdeaho","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.molimm.2017.01.006","article-title":"OX40: Structure and function -What questions remain?","volume":"83","author":"J Willoughby","year":"2017","journal-title":"Mol Immunol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s10620-020-06454-5","article-title":"Enteric-Release Budesonide May Be Useful in the Management of Non-Responsive Celiac Disease","volume":"66","author":"A Therrien","year":"2021","journal-title":"Dig Dis Sci"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMc2112688","article-title":"A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease","volume":"385","author":"D Schuppan","year":"2021","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/S2468-1253(22)00428-9","article-title":"Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study","volume":"8","author":"JA Tye-Din","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1053\/j.gastro.2021.03.014","article-title":"TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease: A Randomized, Double-Blind, Placebo-Controlled Study","volume":"161","author":"CP Kelly","year":"2021","journal-title":"Gastroenterology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S2468-1253(23)00107-3","article-title":"Safety and tolerability of KAN-101, a liver-targeted immune tolerance therapy, in patients with coeliac disease (ACeD): a phase 1 trial","volume":"8","author":"JA Murray","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2318-8624.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:13:04Z","timestamp":1740183184000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2318-8624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":19,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2025,2,21]]},"published-print":{"date-parts":[[2025,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2318-8624","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]}}}